

# **Shingles Vaccination: Making every patient interaction count**

# Adverse Event Reporting Statement and Prescribing Information can be found on page 2.

Every week, patients become eligible for the Shingles National Immunisation Programme. Taking a proactive and systematic approach by organising vaccination clinics can help ensure timely vaccination, in a way that is manageable for your practice.

**Are you having an appointment with an eligible patient?** Use this short guide to maximise every chance to inform eligible patients about the opportunity to help protect them from shingles through vaccination.



Explain that shingles is caused by the reactivation of the chickenpox virus (varicella zoster virus)<sup>1</sup>, which around 90% of adults raised in the UK are infected with<sup>2</sup>.



Introduce the Shingles National Immunisation Programme, which provides free vaccination to eligible individuals (see programme eligibility overleaf)<sup>1</sup>.



Share with your patient that **SHINGRIX** (herpes zoster vaccine recombinant, adjuvanted) is a non-live vaccine which helps to protect against shingles and only requires 2-doses<sup>1,3</sup>.

Consider discussing that neither eggs (or egg-derived) or gelatine (or gelatine-derived) materials are used in the SHINGRIX (herpes zoster vaccine recombinant, adjuvanted) formulation, or as raw materials in the routine manufacturing process.



Deliver a clear recommendation for shingles vaccination to the eligible patient, inviting them to receive the vaccine.

"You are eligible for a free shingles vaccine due to \_\_\_\_ (see programme eligibility overleaf). Can I book you an appointment?"

For resources to support you in your implementation of the Shingles National Immunisation Programme, visit illuminate.

A dedicated platform of support for Immunisation Leads and the wider immunisation team, providing peer-led education, practical resources and the opportunity to connect and collaborate with the Immunisation Lead community.

This initiative is organised and funded by GSK and contains promotional information





### Shingles Vaccination: Making every patient interaction count

Eligibility for the Shingles National Immunisation Programme<sup>1</sup>

## How old is your patient?

years or older with a severely weakened immune system (severely immunocompromised) Individuals who turned They're eligible They're eligible now, with no upper age 65 on or after 1st now September 2023 remain limit eligible until they turn 80.

Not eligible

Eligible

Under 18 with a severely weakened immune system

Under 65 - they will be eligible when they turn 65; Born before 1st Sept 1958 - they will be eligible when they turn 70

80 and over without a severely weakened immune system

Click here for SHINGRIX (herpes zoster vaccine recombinant, adjuvanted)

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at <a href="https://yellowcard.mhra.gov.uk/">https://yellowcard.mhra.gov.uk/</a> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com

#### References

- 1. UKHSA Green Book: Shingles (Herpes Zoster): The Green Book Chapter
- 2. UKHSA Green Book: Varicella: The Green Book Chapter
- 3. SHINGRIX (herpes zoster vaccine recombinant, adjuvanted)
  Summary of Product Characteristics (United Kingdom)

